We found no statistically significant differences in the rate of apoptosis in CD19+ as well as CD3+ cells between the groups of CLL patients stratified by genotype at all the studied polymorphic sites of the CDKN1B and CCND2 genes (Table 6 and Table S5). The gene discussed is CCND2; the disease is B-cell chronic lymphocytic leukemia.